Biologics work by targeting proteins that cause inflammation in ulcerative colitis. As a result, certain biologics help decrease flare-ups and complications. There are four types of biologics ...

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and ...

Failure of integrin inhibitors in clinical trials can be avoided by redesigning the chemical conformation of these proteins, as shown by a study led by Timothy Springer, a professor in the Department ...

Integrin α-4/β-7 - also known as Lymphocyte Peyer’s patch adhesion molecule-1 (LPAM-1) - is an integrin heterodimer composed of covalently linked α-4 and β-7 subunits. Expressed on the surface of ...

Pliant Therapeutics has shown positive interim results in clinical trials for PLN-74809, including a Phase 2a trial for the treatment of IPF. Pliant has several advantages over its competitors, ...

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics ...

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related diseases. Its lead drug, bexotegrast, is being ...

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the role of integrin signaling in vascular dysfunction associated with severe acute respiratory syndrome coronavirus ...